Plain-English translation of NCT07025200 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Asthma research guide →This is a small pilot study testing whether , an injectable medication, can help people with severe asthma by reducing mucus plugs in the lungs and lowering inflammation. The medication works by targeting Type 2 asthma, a specific type of asthma driven by certain immune responses. Researchers want to understand how this treatment affects your lungs and how you feel.
Severe asthma can be hard to control even with strong medications, and mucus buildup in the airways makes breathing harder. This trial is exploring whether this medication can tackle both the mucus and the underlying inflammation that makes severe asthma so difficult to manage.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the medication every 2 weeks for 22 weeks, visiting the clinic each time for check-ups and to receive your dose. Before treatment starts and again after 22 weeks, you'll have lung imaging and a bronchoscopy procedure (where doctors gently look inside your airways and collect small samples). Between visits, you'll answer questions about how your asthma is feeling and have blood tests and breathing tests done to track how you're doing.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Austria
Sponsor
Medical University of Vienna
Enrollment target
~10 participants
Started
February 2023
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Marco Idzko, M.D.
Medical University of Vienna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.